Novartis Lamisil One-Week Cure Ad Claims Substantiated - NAD
This article was originally published in The Tan Sheet
Executive Summary
Novartis Consumer Health's Lamisil AT "cures with just one week's use" advertising claim for the treatment of athlete's foot is not likely to mislead consumers, the National Advertising Division of the Council of Better Business Bureaus determined.
You may also be interested in...
Lotrimin Ultra Antifungal Switch Approved By FDA
Schering-Plough's Lotrimin Ultra will launch nationwide in the first quarter of 2002, marking the third generation of OTC athlete's foot antifungals to bear the Lotrimin name
Lotrimin Ultra Antifungal Switch Approved By FDA
Schering-Plough's Lotrimin Ultra will launch nationwide in the first quarter of 2002, marking the third generation of OTC athlete's foot antifungals to bear the Lotrimin name
Lotrimin Ultra Antifungal Switch Approved By FDA
Schering-Plough's Lotrimin Ultra will launch nationwide in the first quarter of 2002, marking the third generation of OTC athlete's foot antifungals to bear the Lotrimin name